Volume | 23,294 |
|
|||||
News | - | ||||||
Day High | 4.8966 | Low High |
|||||
Day Low | 4.405 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moleculin Biotech Inc | MBRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.50 | 4.405 | 4.8966 | 4.3082 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
430 | 23,294 | $ 4.67 | $ 108,798 | - | 4.28 - 15.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:44:03 | 8 | $ 4.79 | USD |
Moleculin Biotech Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
160.05M | 33.41M | - | 0 | -29.77M | -0.89 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Moleculin Biotech News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.59 | 4.8966 | 4.28 | 4.40 | 12,945 | 0.20 | 4.36% |
1 Month | 5.79 | 6.09 | 4.28 | 4.92 | 24,765 | -1.00 | -17.27% |
3 Months | 7.5615 | 10.35 | 4.28 | 7.15 | 113,153 | -2.77 | -36.65% |
6 Months | 7.335 | 15.75 | 4.28 | 8.61 | 149,234 | -2.55 | -34.70% |
1 Year | 10.80 | 15.75 | 4.28 | 8.86 | 153,256 | -6.01 | -55.65% |
3 Years | 52.2345 | 59.85 | 4.28 | 24.65 | 162,271 | -47.44 | -90.83% |
5 Years | 20.55 | 131.70 | 4.28 | 26.71 | 965,870 | -15.76 | -76.69% |
Moleculin Biotech Description
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. |